Two Sigma Advisers
AYTU icon

Two Sigma Advisers’s AYTU BioPharma AYTU Stock Holding History

Two Sigma Advisers’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-42,500
Closed -$111K – 227
2025
Q4 		$111K Buy
42,500
+2,700
+7% +$6.06K ﹤0.01% 2211
2025
Q3 		$74.8K Buy
+39,800
New +$92K ﹤0.01% 2248
2023
Q1 		– Sell
-1,215
Closed -$4.59K – 2589
2022
Q4 		$4.59K Sell
1,215
-40
-3% -$151 ﹤0.01% 2478
2022
Q3 		$5K Sell
1,255
-105
-8% -$797 ﹤0.01% 2500
2022
Q2 		$19K Buy
1,360
+175
+15% +$2.24K ﹤0.01% 2551
2022
Q1 		$26K Buy
1,185
+313
+36% +$7.78K ﹤0.01% 2645
2021
Q4 		$24K Buy
+872
New +$37.7K ﹤0.01% 2538
2021
Q2 		– Sell
-731
Closed -$111K – 2447
2021
Q1 		$111K Buy
+731
New +$116K ﹤0.01% 2433

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CAM
Crown Advisors Management Larkspur, California $151M AUM 73.11% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers's AYTU Position: Q1 2026 in Review

Two Sigma Advisers sold out of AYTU BioPharma (AYTU) in Q1 2026, closing a stake of 42,500 shares — an estimated $111K sold.

Two Sigma Advisers first reported a position in AYTU in Q1 2021 and held it in 8 quarters. The position peaked at $111K in Q1 2021. 37 funds tracked by Wall St. Rank hold AYTU as of Q1 2026.

  • Two Sigma Advisers reported no remaining AYTU BioPharma position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 42,500 AYTU BioPharma shares in Q1 2026, an estimated $111K.
  • Two Sigma Advisers first reported a position in AYTU BioPharma in Q1 2021 and held it in 8 quarters.
  • Two Sigma Advisers's AYTU BioPharma position peaked at $111K in Q1 2021.
  • 37 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.